AbCellera Q1 Revenue $8.3M Beats Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 11 2026
0mins
Reports Q1 revenue $8.3M, consensus $5.8M. "We are excited to share interim Phase 1 data that show ABCL635 achieved robust NK3R target engagement at doses that were well-tolerated in healthy volunteers and a pharmacokinetic profile that may support a once monthly dosing regimen. We look forward to the efficacy readout from the Phase 2 data in Q3, which we believe will be highly de-risking for the program," said Carl Hansen, Ph.D., founder and CEO of AbCellera. "Through 2026 we are focused on delivering data readouts for our clinical programs, advancing ABCL688 and ABCL386 into IND-enabling studies, and selecting at least one additional development candidate. We continue to maintain our strong cash position, ending the quarter with approximately $655 million dollars in available liquidity to execute on our strategy."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ABCL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ABCL
Wall Street analysts forecast ABCL stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 5.730
Low
9.00
Averages
9.00
High
9.00
Current: 5.730
Low
9.00
Averages
9.00
High
9.00
About ABCL
AbCellera Biologics Inc. discovers and develops antibody medicines for indications across therapeutic areas, including cancer, metabolic and endocrine conditions, and autoimmune disorders. Its platform integrates technology, data science, infrastructure, and interdisciplinary teams to solve the challenging antibody discovery problems. It is focused on advancing an internal pipeline of programs and collaborating on drug development programs with partners. Its first two internal programs, ABCL635 and ABCL575, are in late-preclinical studies. ABCL635 is an antibody drug candidate for metabolic and endocrine conditions, and ABCL575 is an antibody drug candidate with broad potential in inflammatory conditions and autoimmune diseases and an initial indication in atopic dermatitis. ABCL575 binds OX40L to disrupt OX40/OX40L signaling, a regulator of inflammatory pathways in AD. In addition to ABCL635 and ABCL575, it is advancing a pipeline of more than 20 internal discovery programs.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
AbCellera Biologics Q1 2026 Earnings Call Insights Highlight Key Developments
- Key Data Release in 2026: CEO Carl L. Hansen emphasized that 2026 is poised to be pivotal, with the top-line readout for ABCL635 Phase II expected in Q3, representing a potential first-in-class antibody for non-hormonal menopausal vasomotor symptoms, with a market potential exceeding $6 billion.
- Financial Performance Overview: The company reported approximately $8 million in revenue for Q1, primarily from research fees, while R&D expenses were around $47 million, leading to a net loss of about $43 million, indicating ongoing financial pressure as the focus shifts to internal pipeline development.
- Clinical Progress and Candidates: Management indicated that beyond ABCL635 and ABCL575, up to three additional clinical-stage programs are expected by the end of 2027, with plans to select a fifth development candidate in the first half of this year, showcasing the company's commitment to R&D.
- Liquidity and Funding Status: CFO Andrew Booth noted that the company has approximately $530 million in cash and equivalents, along with about $655 million in available liquidity, ensuring the ability to sustain its R&D strategy over the next three years.
See More
AbCellera Biologics to Announce Q1 Earnings on May 11
- Earnings Announcement Date: AbCellera Biologics is set to release its Q1 2023 earnings report on May 11 after market close, drawing significant attention from investors regarding its performance.
- EPS Expectations: The consensus EPS estimate stands at -$0.20, indicating challenges in profitability that may affect investor confidence and stock performance.
- Revenue Growth Forecast: Revenue is projected at $5.84 million, reflecting a 39.0% year-over-year increase, showcasing the company's growth potential in the market despite the downward revisions in EPS expectations.
- Revision Trends Analysis: Over the past three months, there have been no upward revisions in EPS estimates, with one downward revision, while revenue estimates have seen three downward adjustments, indicating a cautious market outlook on the company's future performance.
See More
ABCL635 Non-Hormonal Treatment Progresses Significantly
- Clinical Trial Progress: ABCL635, a candidate for non-hormonal treatment of menopause-related vasomotor symptoms, is set to release key clinical data, potentially addressing a multi-billion-dollar market need and marking ABCL's transition to a fully integrated clinical-stage biotech.
- Strong Stock Surge: ABCL shares closed up 9% on Friday and gained an additional 4% after hours, totaling an 18% increase for the week, reflecting investor anticipation for the upcoming Q1 2026 earnings report and clinical catalysts, indicating strong market confidence in the company's future.
- Optimistic Analyst Ratings: According to Koyfin, 8 out of 9 analysts covering ABCL stock rate it as ‘Buy’ or higher, with only 1 rating it ‘Hold’; the 12-month average price target is $9.14, suggesting a potential upside of about 74% from the last close, further boosting investor sentiment.
- Institutional Investor Increase: Baker Bros. Advisors has increased its stake in AbCellera to 10.8%, signaling strong institutional confidence in ABCL's future, which has further fueled positive market sentiment around the stock.
See More
AbCellera to Reveal Interim Results for ABCL635 in Q1 2026 Earnings Call
- Clinical Trial Progress: AbCellera will disclose interim results from the Phase 1 study of ABCL635 during its Q1 2026 earnings call on May 11, 2026, including safety, pharmacokinetic, and pharmacodynamic data, marking a significant advancement in the treatment of menopause-related symptoms.
- New Drug Development Context: ABCL635 is a potential first-in-class antibody therapeutic targeting the neurokinin 3 receptor for the non-hormonal treatment of moderate-to-severe vasomotor symptoms, expected to provide new treatment options in women's health and fill a market gap.
- Trial Design Details: The ongoing multicenter, randomized, double-blind, placebo-controlled Phase 2 study is anticipated to yield results in Q3 2026, further validating the drug's clinical efficacy and safety profile.
- Strategic Company Positioning: As the first program from AbCellera's GPCR and ion channel platform, the clinical progress of ABCL635 not only showcases the company's R&D capabilities but also has the potential to enhance its market position in the biotechnology sector, attracting more investor interest.
See More
AbCellera to Announce Q1 2026 Financial Results
- Earnings Announcement Schedule: AbCellera is set to release its Q1 2026 financial results on May 11, 2026, and will hold an earnings conference call at 2:00 PM Pacific Time (5:00 PM Eastern Time) to discuss its financial performance and future outlook.
- Live Webcast Availability: The earnings call will feature a live audio webcast accessible through AbCellera's Investor Relations website, ensuring that investors and stakeholders can stay updated with the company's latest developments in real-time.
- Replay Functionality: A replay of the earnings call will be available through the same link after the conference, allowing investors who could not attend live to review the meeting content, thereby enhancing information transparency.
- Company Background: AbCellera is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody-based medicines in areas such as endocrinology, women's health, immunology, and oncology, committed to advancing innovative healthcare solutions.
See More
Axon Reports Q4 Revenue and Earnings Beat Estimates
- Significant Revenue Growth: Axon reported fourth-quarter revenue of $796.72 million, surpassing analyst expectations of $755.40 million, indicating strong market performance and sustained growth potential for the company.
- Improved Profitability: The company posted adjusted earnings of $2.15 per share, significantly exceeding the analyst estimate of $1.60 per share, reflecting Axon's success in cost control and operational efficiency.
- Stock Price Surge: Axon's shares jumped 16.2% in pre-market trading to $514.21, demonstrating a positive market reaction to its earnings report and indicating increased investor confidence in the company's future prospects.
- Market Impact Analysis: This earnings beat not only enhances Axon's market valuation but may also attract more investor attention, further solidifying the company's leadership position in the security technology sector.
See More
AbCellera Biologics Q1 2026 Earnings Call Insights Highlight Key Developments
- Key Data Release in 2026: CEO Carl L. Hansen emphasized that 2026 is poised to be pivotal, with the top-line readout for ABCL635 Phase II expected in Q3, representing a potential first-in-class antibody for non-hormonal menopausal vasomotor symptoms, with a market potential exceeding $6 billion.
- Financial Performance Overview: The company reported approximately $8 million in revenue for Q1, primarily from research fees, while R&D expenses were around $47 million, leading to a net loss of about $43 million, indicating ongoing financial pressure as the focus shifts to internal pipeline development.
- Clinical Progress and Candidates: Management indicated that beyond ABCL635 and ABCL575, up to three additional clinical-stage programs are expected by the end of 2027, with plans to select a fifth development candidate in the first half of this year, showcasing the company's commitment to R&D.
- Liquidity and Funding Status: CFO Andrew Booth noted that the company has approximately $530 million in cash and equivalents, along with about $655 million in available liquidity, ensuring the ability to sustain its R&D strategy over the next three years.
See More
AbCellera Biologics to Announce Q1 Earnings on May 11
- Earnings Announcement Date: AbCellera Biologics is set to release its Q1 2023 earnings report on May 11 after market close, drawing significant attention from investors regarding its performance.
- EPS Expectations: The consensus EPS estimate stands at -$0.20, indicating challenges in profitability that may affect investor confidence and stock performance.
- Revenue Growth Forecast: Revenue is projected at $5.84 million, reflecting a 39.0% year-over-year increase, showcasing the company's growth potential in the market despite the downward revisions in EPS expectations.
- Revision Trends Analysis: Over the past three months, there have been no upward revisions in EPS estimates, with one downward revision, while revenue estimates have seen three downward adjustments, indicating a cautious market outlook on the company's future performance.
See More
ABCL635 Non-Hormonal Treatment Progresses Significantly
- Clinical Trial Progress: ABCL635, a candidate for non-hormonal treatment of menopause-related vasomotor symptoms, is set to release key clinical data, potentially addressing a multi-billion-dollar market need and marking ABCL's transition to a fully integrated clinical-stage biotech.
- Strong Stock Surge: ABCL shares closed up 9% on Friday and gained an additional 4% after hours, totaling an 18% increase for the week, reflecting investor anticipation for the upcoming Q1 2026 earnings report and clinical catalysts, indicating strong market confidence in the company's future.
- Optimistic Analyst Ratings: According to Koyfin, 8 out of 9 analysts covering ABCL stock rate it as ‘Buy’ or higher, with only 1 rating it ‘Hold’; the 12-month average price target is $9.14, suggesting a potential upside of about 74% from the last close, further boosting investor sentiment.
- Institutional Investor Increase: Baker Bros. Advisors has increased its stake in AbCellera to 10.8%, signaling strong institutional confidence in ABCL's future, which has further fueled positive market sentiment around the stock.
See More
AbCellera to Reveal Interim Results for ABCL635 in Q1 2026 Earnings Call
- Clinical Trial Progress: AbCellera will disclose interim results from the Phase 1 study of ABCL635 during its Q1 2026 earnings call on May 11, 2026, including safety, pharmacokinetic, and pharmacodynamic data, marking a significant advancement in the treatment of menopause-related symptoms.
- New Drug Development Context: ABCL635 is a potential first-in-class antibody therapeutic targeting the neurokinin 3 receptor for the non-hormonal treatment of moderate-to-severe vasomotor symptoms, expected to provide new treatment options in women's health and fill a market gap.
- Trial Design Details: The ongoing multicenter, randomized, double-blind, placebo-controlled Phase 2 study is anticipated to yield results in Q3 2026, further validating the drug's clinical efficacy and safety profile.
- Strategic Company Positioning: As the first program from AbCellera's GPCR and ion channel platform, the clinical progress of ABCL635 not only showcases the company's R&D capabilities but also has the potential to enhance its market position in the biotechnology sector, attracting more investor interest.
See More
AbCellera to Announce Q1 2026 Financial Results
- Earnings Announcement Schedule: AbCellera is set to release its Q1 2026 financial results on May 11, 2026, and will hold an earnings conference call at 2:00 PM Pacific Time (5:00 PM Eastern Time) to discuss its financial performance and future outlook.
- Live Webcast Availability: The earnings call will feature a live audio webcast accessible through AbCellera's Investor Relations website, ensuring that investors and stakeholders can stay updated with the company's latest developments in real-time.
- Replay Functionality: A replay of the earnings call will be available through the same link after the conference, allowing investors who could not attend live to review the meeting content, thereby enhancing information transparency.
- Company Background: AbCellera is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody-based medicines in areas such as endocrinology, women's health, immunology, and oncology, committed to advancing innovative healthcare solutions.
See More
Axon Reports Q4 Revenue and Earnings Beat Estimates
- Significant Revenue Growth: Axon reported fourth-quarter revenue of $796.72 million, surpassing analyst expectations of $755.40 million, indicating strong market performance and sustained growth potential for the company.
- Improved Profitability: The company posted adjusted earnings of $2.15 per share, significantly exceeding the analyst estimate of $1.60 per share, reflecting Axon's success in cost control and operational efficiency.
- Stock Price Surge: Axon's shares jumped 16.2% in pre-market trading to $514.21, demonstrating a positive market reaction to its earnings report and indicating increased investor confidence in the company's future prospects.
- Market Impact Analysis: This earnings beat not only enhances Axon's market valuation but may also attract more investor attention, further solidifying the company's leadership position in the security technology sector.
See More
